Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock.
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial [Yahoo! Finance]Yahoo! Finance
- LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D [Yahoo! Finance]Yahoo! Finance
- Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern [Yahoo! Finance]Yahoo! Finance
- RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results [Yahoo! Finance]Yahoo! Finance
- Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- 3/17/26 - Form 4
- LLY's page on the SEC website